leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...164165166167168169170171172173174...235236»
  • ||||||||||  ceftriaxone / Generic Mfg.
    Ocular toxoplasmosis without laboratory confirmation: a challenging diagnosis () -  Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1155;    
    The diagnosis was reconsidered, the ceftriaxone was discontinued and the patient was commenced on a loading dose of oral pyrimethamine 200mg followed by 50mg daily in combination with oral folinic acid 15mg three times a week to retard the dose-related suppression of the bone marrow, sulfadiazine 500mg three times per day and a reducing dose of oral prednisolone 50mg for possible ocular toxoplasmosis (despite negative serum IgM and IgG anti-Toxoplasma antibodies titers). Despite negative serology ocular toxoplasmosis should be considered in the diagnosis of posterior uveitis if the clinical picture is compatible.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda
    Review, Journal:  Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) -  Sep 26, 2019   
    The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Shire Pharmaceuticals) of pegylated liposomal irinotecan hydrochloride trihydrate (liposomal irinotecan) to submit clinical and cost-effectiveness evidence for its use in combination with 5-fluorouracil (5-FU) and folic acid/leucovorin (LV) for treating patients with pancreatic cancer following prior treatment with gemcitabine as part of the institute's Single Technology Appraisal process...The company, ERG and Appraisal Committee (AC) all agreed that oxaliplatin + 5-FU/LV is the most commonly used treatment...Therefore, despite uncertainty around the clinical-effectiveness evidence and cost-effectiveness results, the AC was confident that the ICER was in excess of £50,000 per QALY gained. The final guidance issued by NICE is that liposomal irinotecan + 5-FU/LV is not recommended within its marketing authorisation for treating metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy.
  • ||||||||||  leucovorin calcium / generics
    Comparison of Hematological Toxicity of mFOLFOX6 vs CAPOX Chemotherapy Regimens in Adjuvant Treatment of Stage II-III Colon Cancer Patients (Cellular Therapy) -  Sep 26, 2019 - Abstract #SOHO2019SOHO_461;    
    Thrombocytopenia G1/G2 occurred during 19 (12%) and 3 (3.85%) cycles, G3-G4 were during 3 (1,9%) and 0 in Arm A and Arm B, respectively. In Arm A G1/G2 anemia was observed in 43 (27,38%) cycles, meanwhile in Arm B - during 27 (34,6%) cycles, no G3/G4 anemia was seen.Conclusion These data suggest that CAPOX chemotherapy regimen is associated with less G3/G4 hematological toxicity than mFOLFOX6 and can be used safely during daily practice in prescribing adjuvant chemotherapy for colon cancer.
  • ||||||||||  leucovorin calcium / generics, fluorouracil / generics
    Clinical, Journal:  Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration. (Pubmed Central) -  Sep 26, 2019   
    Six months of oxaliplatin-based therapy still remain the standard of care. Decisions to shorten the duration of adjuvant oxaliplatin-based therapy should be dictated by drug tolerability, risk stratification of the disease, consideration of the value of decreased neurotoxicity at the cost of decreased DFS, and patient preference.
  • ||||||||||  doxycycline / Generic Mfg.
    SEVERE PNEUMONITIS AND PULMONARY FIBROSIS RELATED TO A COMMON CHEMOTHERAPY AGENT (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 4) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_2415;    
    Alternative regimens include atovaquone and pyrimethamine (3). She was recently diagnosed with metastatic sigmoid colorectal cancer and received FOLFOX chemotherapy (Folinic acid, 5-Fluorouracil and Oxaliplatin)...She was initially treated with vancomycin, levofloxacin and doxycycline for presumed pneumonia...Hence, she was started on methylprednisolone...Most cases of oxaliplatin associated pulmonary fibrosis reported in literature have a rapid and fatal course similar to our patient.
  • ||||||||||  leucovorin calcium / generics, fluorouracil / generics
    LEUCOVORIN: A RARELY REPORTED CAUSE OF HYPERSENSITIVITY (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 2) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_2349;    
    Prompt recognition and supportive treatment would significantly impact patient outcomes. Additionally, it could lead to the development of preventive therapy such as Powell's intravenous desensitization with Leucovorin.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly
    Trial completion, Combination therapy, Metastases:  A Study in Second Line Metastatic Colorectal Cancer (clinicaltrials.gov) -  Sep 25, 2019   
    P3,  N=1072, Completed, 
    Additionally, it could lead to the development of preventive therapy such as Powell's intravenous desensitization with Leucovorin. Active, not recruiting --> Completed
  • ||||||||||  leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
    Long Term Efficacy of Preoperative Chemotherapy or Chemoradiotherapy Combined with Total Mesorectal Excision for Locally Advanced Rectal Cancer: Retrospectiveanalysis of 305 Patients (ASTRO Innovation Hub) -  Sep 24, 2019 - Abstract #ASTRO2019ASTRO_4177;    
    Besides, the other critical factors in the strategy design for rectal cancer such as MRF, EMVI should be further evaluated between these two arms. Table:The baseline information of the patients In total Preoperative chemotherapy preoperative chemoradiotherapy P value Age ＞65 66(21.6%) 12(22%) 53(21.5%) 0.93 ≤65 239(78.4%) 46(78%) 193(78.5%) Sex male 207(67.8%) 37(62.7%) 170(69.1%) 0.10 female 98(32.2%) 22(37.3%) 76(30.9%) Tumor location Upper Rectum 20(6.6%) 20(34%) 0 ＜0.001 Middle Rectum 96(31.4%) 25(42.4%) 71(28%) Lower Rectum 189（62%） 14（23.7%） 175（72%） Stage II（T3-4N0-1） 53（17.4%） 7（11.9%） 46（18.7%） 0.052 III 251（82.3%） 51（86.4%） 200（81.3%） IV 1（0.3%） 1（1.7%） 0
  • ||||||||||  Otrexup (methotrexate) / Assertio, Rituxan (rituximab) / Roche
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) -  Sep 23, 2019   
    P2,  N=12, Completed, 
    Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021 Recruiting --> Completed | N=28 --> 12 | Trial completion date: Jul 2021 --> Sep 2019 | Trial primary completion date: Jul 2020 --> Sep 2019
  • ||||||||||  Trial completion date, Trial primary completion date:  IPLUS: Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 (clinicaltrials.gov) -  Sep 22, 2019   
    P1/2,  N=43, Recruiting, 
    Recruiting --> Completed | N=28 --> 12 | Trial completion date: Jul 2021 --> Sep 2019 | Trial primary completion date: Jul 2020 --> Sep 2019 Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Dec 2020
  • ||||||||||  leucovorin calcium / generics, fluorouracil / generics
    Clinical, Journal, Adverse events:  Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients. (Pubmed Central) -  Sep 19, 2019   
    It seems that the adverse drug reactions of FOLFOX regimen were more favorable than DCF regimen. The results of this study may help clinicians choosing a more favorable chemotherapy regimen especially in patients with a low performance status who have difficulties in tolerating a chemotherapy regimen with a more severe adverse effect profile.
  • ||||||||||  proTide 5-fluorouracil (NUC-3373) / NuCana BioMed
    Inhibition of thymidylate synthase by the ProTide NUC-3373: in vitro analysis and clinical validation (Board 59: Level 2 - Hall D) -  Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_491;    
    P1
    Formation of long-lasting ternary complexes and increased cytoplasmic expression suggest that NUC-3373 is a potent inhibitor of TS activity. Data describing whether LV potentiates the impact of NUC-3373 on TS in patients will be presented.
  • ||||||||||  oxaliplatin / Generic Mfg.
    Tumor-targeted and pH-shiftable nanoparticles to encapsulate oxaliplatin and microRNA for colorectal cancer therapy (Board 100: Level 2 - Hall D) -  Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_136;    
    We demonstrated that the upregulation of apoptosis pathway and the downregulation of β-catenin pathway were accounted for the efficient antitumor effect. In conclusion, the delivery of miR-c and Oxa in pH-sensitive and peptide-modified nanoparticles may provide a novel and potential strategy for colorectal cancer treatment.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg.
    Clinical, Clinical guideline, Journal:  Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. (Pubmed Central) -  Sep 18, 2019   
    Endorsed recommendations from the 2016 version of this guideline for computed tomography, baseline performance status and comorbidity profile, defining goals of care, first-line therapy, and palliative care are also contained within the full guideline text. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
  • ||||||||||  Trial completion date, Metastases:  Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) -  Sep 16, 2019   
    P2,  N=50, Active, not recruiting, 
    Trial completion date: Jun 2019 --> Feb 2020 Trial completion date: Jul 2019 --> Mar 2020
  • ||||||||||  Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen
    Journal:  Acute bone marrow suppression and gastrointestinal toxicity following acute oral methotrexate overdose. (Pubmed Central) -  Sep 16, 2019   
    The serum methotrexate concentrations were below the treatment threshold of the folinic acid rescue therapy nomogram suggesting that the nomogram should not be relied on in acute ingestions. Large acute oral methotrexate poisoning can result in systemic toxicity and folinic acid therapy should be provided in ingestions >1000 mg.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Retrospective data, Journal, Mismatch Repair:  Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. (Pubmed Central) -  Sep 14, 2019   
    P3
    The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial...Patients in the clinical trials were randomly assigned to receive 6 months of chemotherapy with FOLFOX or FOLFOX plus cetuximab...The deficient MMR phenotype remains a favorable prognostic factor in patients with stage III colon cancer receiving FOLFOX adjuvant chemotherapy. clinicaltrials.gov Identifier: NCT00079274 for the NCCTG N0147 trial and EudraCT identifier: 2005-003463-23 for the PETACC8 trial.